ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea · Delayed Price · Currency is KRW 2,925.00
-15.00 (-0.51%)
At close: Oct 23, 2026
ImmuneOncia Therapeutics Revenue
In the year 2025, ImmuneOncia Therapeutics had annual revenue of 111.21M KRW, down -83.01%. That makes ImmuneOncia Therapeutics the 46,599th largest company in the world by revenue and 2,607th in South Korea.
Revenue
111.21M
Revenue Growth
-83.01%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
267.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 111.21M | -543.33M | -83.01% |
| Dec 31, 2024 | 654.54M | 544.54M | 495.04% |
| Dec 31, 2023 | 110.00M | -7.62B | -98.58% |
| Dec 31, 2022 | 7.73B | 7.70B | 21,413.30% |
| Dec 31, 2021 | 35.95M | 33.45M | 1,337.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| Ahn-Gook Pharmaceutical | 345.08B |
| Kyung Dong Pharmaceutical | 201.12B |
| GC WellBeing | 192.21B |
| DAE HWA Pharmaceutical | 148.75B |
| HYUNDAI BIOLAND | 140.70B |
| OPTUS Pharmaceutical | 94.47B |
| Vivozon Pharmaceutical | 50.34B |